CD44 expression predicts disease outcome in localized large B cell lymphoma

Leukemia

Volumn 13, Issue 9, 1999, Pages 1448-1455

  Drillenburg, P ^a   Wielenga, Vjm ^a   Kramer, Mhh ^b   Van Krieken, J H J M ^b   Kluin Nelemans, Hc ^b,c   Hermans, J ^b,c   Heisterkamp, S ^a   Noordijk, E M ^b,c   Kluin, P M ^b,c   Pals, S T ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Integraal Kankercentrum West   (Netherlands)

Author keywords

B cell lymphoma; CD44; Cell adhesion; Prognosis

Indexed keywords

ANTIBODY; HERMES ANTIGEN; HOMING RECEPTOR; REAGENT;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CANCER MORTALITY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032820878     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401490     Document Type: Article

References (48)

1. Stein H, Dallenbach F. Diffuse large cell lymphomas of B and T cell type. In Knowles DM (ed). Neoplastic Hematopathology. Williams and Wilkins: Baltimore, 1992, pp 675-714.
2. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA. Perspective: a revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
3. Klein U, Goossens T, Fischer M, Kanzler H, Braeuninger A, Rajewsky, Kuppers R. Somatic hypermutation in normal and transformed B cells. Immunol Rev 1998; 162: 261-280.
4. Kramer MHH, Hermans J, Parker J, Krol ADG, Kluin-Nelemans JC, Haak HL, van Groningen K, van Krieken JHJM, de Jong D, Kluin PhM. The clinical significance of BCL2 and p53 protein expression in diffuse large B-cell lymphoma: a population based study. J Clin Oncol 1996; 14: 2131-2138.
5. Dalla-Favera R. BCL-6 in diffuse large-cell lymphomas. In: DeVita VT, Hellman S, Rosenberg SA (eds). Important Advances in Oncology Lippencott: Philadelphia, 1996, pp 139-159.
6. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model of aggressive non-Hodgkin's lymphoma. New Engl J Med 1993; 329: 987-994.
7. Lesley J, Hyman R, Kincade PW. CD44 and its interactions with the extracellular matrix. Adv Immunol 1993; 54: 271-335.
8. Jalkanen S, Bargatze RF, Herron LR, Butcher EC. A lymphoid cell surface glycoprotein involved in endothelial cell recognition and lymphocyte homing in man. Eur J Immunol 1986; 16: 1195-1202.
9. Huet S, Groux H, Caillou B, Valentin H, Prieur AM, Bernard A. CD44 contributes to T cell activation. J Immunol 1989; 143: 798-801.
10. Koopman G, van Kooyk Y, de Graaf M, Meijer CJLM, Figdor CG, Pals ST. Triggering of the CD44 antigen on T lymphocytes promotes T cell adhesion through the LFA-1 pathway. J Immunol 1990; 145: 3589-3593.
11. Miyake K, Medina KL, Hayashi S, Ono S, Hamaoka T, Kincade PW. Monoclonal antbodies to Pgp-1/CD44 block lympho-hemopoiesis in long-term bone marrow cultures. J Exp Med 1990; 171: 477-488.
12. Pals ST, Horst E, Ossekoppele CJ, Figdor CG, Scheper RJ, Meijer CJLM. Expression of lymphocyte homing receptor as a mechanism of dissemination in non-Hodgkin's lymphoma. Blood 1989; 73: 885-888.
13. Günthert U, Hofman M, Rudy W, Reber S, Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cell lines. Cell 1991; 65: 13-24.
14. Jalkanen S, Joensuu H, Soderstrom KO, Klemi P. Lymphocyte homing and clinical behaviour of non-Hodgkin's lymphoma. J Clin Invest 1991; 87: 1835-1840.
15. Sy MS, Guo YJ, Stamenkovic I. Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med 1991; 174: 859-866.
16. Wielenga VJM, Heider KH, Offerhaus GJA, Adolf GR, van den Berg F, Ponta H, Herrlich P, Pals ST. Expression of CD44 splice variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993; 53: 4754-4756.
17. Stamenkovic I, Amiot M, Pesando JM, Seed B. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 1989; 56: 1057-1062.
18. Screaton GR, Bell MV, Jackson DC, Cornelis FB, Gerth K, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992; 89: 12160-12164.
19. Jackson D, Bell JI, Dickinson R, Timans J, Shields J, Whittle N. Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. J Cell Biol 1995; 128: 673-685.
20. Koopman G, Heider KH, Horst E, Adolf GR, van den Berg F, Ponta H, Herrlich P, Pals ST. Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med 1993; 177: 897-904.
21. Stauder R, Eisterer W, Thaler J, Gunthert U. CD44 variant isoforms in non-Hodgkin's lymphomas: a new independent prognostic factor. Blood 1995; 85: 2885-2899.
22. Terpe HJ, Koopmann R, Imhof BA, Gunthert U. Expression of integrins and CD44 isoforms in non-Hodgkin's lymphomas: CD44 variant isoforms are preferentially expressed in high-grade malignant lymphomas. J Pathol 1994; 174: 89-100.
23. Salles G, Zain M, Jiang W-M, Boussiotis VA, Shipp MA. Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells. Blood 1993; 82: 3539-3547.
24. Horst E, Meijer CJLM, Radaszkiewicz T, Ossekoppele GJ, van Krieken JHJM, Pals ST. Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). Leukemia 1990; 4: 595-599.
25. Jalkanen S, Joensuu H, Klemi P. Prognostic value of lymphocyte homing receptor and S phase fraction in non-Hodgkin's lymphoma. Blood 1990; 75: 1549-1556.
26. Yakushijin Y, Steckel J, Kharbanda S, Hasserjian R, Neuberg D, Jiang W-M, Anderson I, Shipp MA. A directly spliced exon 10-containing CD44 variant promotes the metastasis and homotypic aggregation of aggressive non-Hodgkin's lymphoma. Blood 1998; 91: 4282-4291.
27. Kramer MHH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JHJM, de Jong D, Maartense E, Schuuring E, Kluin PhM. Clinical relevance of BCL2, BCL6 and myc rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92: 3152-3162.
28. Krol AD, Hermans J, Kramer MHH, Kluin PhM, Kluin-Nelemans HC, Blok P, Heering KJ, Noordijk EM, van Krieken JHJM. Gastric lymphomas compared with lymph node lymphomas in a population-based registry differ in stage distribution and dissemination patterns but not in patient survival. Cancer 1997; 79: 390-397.
29. Krol AD, Hermans J, Dawson L, Snijder S, Wijermans PW, Kluin-Nelemans HC, Kluin PhM, van Krieken JHJM, Noordijk EM. Treatment, patterns of failure and survival of stage I nodal and extranodal non-Hodgkin's lymphomas in the Comprehensive Cancer Centre West population based registry. Cancer 1998; 83: 1612-1619.
30. Hermans J, Krol ADG, van Groningen K, Kluin PhM, Kluin-Nelemans JC, Kramer MHH, Noordijk EM, Ong F, Wijermans PW. International prognostic index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 1995; 86: 1460-1463.
31. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860-1861.
32. Musshoff K. Klinische Stadieneinteilung der nicht-Hodgkin lymphome. Strahlentherapie 1977; 153: 218-221.
33. Stansfeld AG, Diebold J, Kapanci Y, Kelenyi G, Lennert K, Mioduszewska O, Noel H, Rilke F, Sundstrom C, van Unnik JAM, Wright DH. Updated Kiel classification for lymphomas. Lancet 1988; 1: 292-293.
34. Jalkanen S, Bargatze RF, De Los Toyos J, Butcher EC. Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95 kD glycoprotein differentially inhibit binding to lymph node, mucosal and synovial endothelial cells. J Cell Biol 1987; 105: 983-990.
35. Heider KH, Mulder JWR, Ostermann E, Susani E, Patzelt E, Pals ST, Adolf GR. Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumor cells are expressed in normal tissues of humans and cynomolgus monkeys. Eur J Cancer 1995; 31A: 2385-2391.
36. Mulder JWR, Kruyt PM, Sewnath M, Oosting J, Seldenrijk CA, Weidema WF, Offerhaus GJA, Pals ST. Colorectal cancer prognosis and expression of exon-v6 containing CD44 proteins. Lancet 1994; 344: 1470-1472.
37. Ship MA. Can we improve upon the International Index? Ann Oncol 1997; 8 (Suppl. 1): S43-S47.
38. Offit K, Le Cocco F, Louie DC, Parsa NZ, Leung D Portlock C, Ye BH, Lista F, Filippa DA, Rosenbaum A, Ladanyi M, Jhanwar S, Dalla-Favera R, Chaganti RSK. Rearrangement of the BCL6 gene as a prognostic marker in diffuse large cell lymphoma. New Engl J Med 1994; 331: 74-80.
39. van Krieken JHJM, Raffeld M, Raghoebier S, Jaffe ES, van Ommen GJB, Kluin PhM. Molecular genetics of gastrointestinal non-Hodgkin's lymphomas: unusual prevalence and pattern of c-myc rearrangements in aggressive lymphomas. Blood 1990; 76: 797-800.
40. Pals ST, Drillenburg P, Radaszkiewicz T, Manten-Horst E. Adhesion molecules in the dissemination of non-Hodgkin's lymphoma. Acta Haematol 1997; 97: 73-80.
41. Clark RA, Alon R, Springer TA. CD44 and hyaluronan-dependent rolling interactions of lymphocytes on tonsillar stroma. J Cell Biol 1996; 134: 1075-1087.
42. DeGrendele HC, Estess P, Picker LJ, Siegelman MH. CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte-endothelial cell primary adhesion pathway. J Exp Med 1996; 183: 1119-1130.
43. Camp RL, Scheynius A, Johansson C, Pure E. CD44 is necessary for optimal contact allergic responses but is not required for normal leukocyte extravasation. J Exp Med 1993; 178: 497-507.
44. Degrendele HC, Estess P, Siegelman MH. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 1997; 278: 672-675.
45. Kaufmann M, Heider KH, Sinn HP, Minkwitz von G, Ponta H, Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995; 345: 615-619.
46. Yu Q, Toole BP, Stamenkovic I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med 1997; 186: 1985-1996.
47. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. New Engl J Med 1998; 339: 21-26.
48. Horst E, Meijer CJLM, Radaskiewicz Th, Dongen JJM van, Pieters R, Figdor CG, Hooftman A, Pals ST. Expression of a human homing receptor (CD44) in lymphoid malignancies and related stages of lymphoid development. Leukemia 1990; 4: 383-389.